Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suk, R
Park, S
Liu, G
Cogan-Drew, T
Zhou, W
Su, L
Lynch, T
Wain, J
Christiani, D
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：842S / 842S
页数：1
相关论文
共 50 条
  • [21] Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
    Genova, C.
    Rijavec, E.
    Rossi, G.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
  • [23] Survival in untreated early stage non-small cell lung cancer
    Chadha, AS
    Ganti, AK
    Sohi, JS
    Sahmoun, AE
    Mehd, SA
    ANTICANCER RESEARCH, 2005, 25 (05) : 3517 - 3520
  • [24] The prognostic role of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in resected non-small cell lung cancer (NSCLC)
    Geredeli, Caglayan
    Artac, Mehmet
    Yildirim, Selman
    Dede, Isa
    Inal, Ali
    Guler, Tunc
    Boruban, Melih Cem
    Zamani, Ayse Gul
    Bozcuk, Hakan
    Demirkazik, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.
    Zhang, L.
    Zhou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Preoperative Survivin, Ercc1 And Pten Expression In Stage III Non-small Cell Lung Cancer (nsclc) Patients(pts) Treated With Neoadjuvant And Definitive Chemoradiation And Association With Overall Survival (os).
    Batus, M.
    Fidler, M.
    Walters, K. Kaiser
    Pool, M.
    Mahon, B.
    Basu, S.
    Borgia, J. A.
    Sher, D.
    Bonomi, P. D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S238 - S238
  • [27] Polymorphisms of vitamin D receptor and survival in early stage non-small cell lung cancer patients
    Zhou, Wei
    Suk, Rebecca
    Liu, Geoffrey
    Neuberg, Donna S.
    Asomaning, Kofi
    Su, Li
    Wain, John C.
    Lynch, Thomas J.
    Giovannucci, Edward
    Christiani, David C.
    CANCER RESEARCH, 2006, 66 (08)
  • [28] The prognostic role of XRCC1, ERCC1, ERCC2 and, TP53 single nucleotide polymorphisms (SNPs) in metastatic non-small cell lung cancer (NSCLC)
    Artac, M.
    Geredeli, C.
    Yildirim, S.
    Inal, A.
    Guler, T.
    Boruban, C.
    Akkuloglu, T.
    Isikdogan, A.
    Bozcuk, H.
    Demirkazik, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S835 - S836
  • [29] Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS)
    Batus, Marta
    Fidler, Mary J.
    Walters, Kelly Kaiser
    Pool, Mark
    Mahon, Brett
    Basu, Sanjib
    Borgia, Jeffrey Allen
    Sher, David
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)
    Onishchenko, Dmitry
    Dunyak, James
    Masson, Eric
    Helmlinger, Gabriel
    Peskov, Kirill
    Tomkinson, Helen
    Stanski, Donald
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S138 - S138
12345